| Ytd | 27.71% | |
| 1y | 2.81% |
| Open | 6.99 | Prev Close | 7.03 | Low | 6.96 | High | 7.06 | Mkt Cap | 451.32M |
| Vol | 18.86K | Avg Vol | 656.07K | EPS | -1.74 | P/E | -4.04 | Forward P/E | -4.05 |
| Beta | 0.40 | Short Ratio | 4.79 | Inst. Own | 77.55% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 7.09 | 200-d Avg | 6.33 | 1yr Est | 21.83 |
AURA News
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage bi
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA)
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data
Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercializat
Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Compa
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage bio
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natali
Amsterdam, 6 May 2026 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTE
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-
US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 resu
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-
Natalie Holles, seasoned industry executive with significant rare disease operational and commercial
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their
The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While emp
Aura Biosciences, Inc. (AURA) is looking like an interesting pick from a technical perspective, as t
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their
The mean of analysts' price targets for Aura Biosciences (AURA) points to a 201.5% upside in the sto
Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline D
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-
Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr
On Tuesday, 647 companies set new 52-week lows.